186 related articles for article (PubMed ID: 18415123)
1. Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas.
Briese J; Schulte HM; Sajin M; Bamberger C; Redlin K; Milde-Langosch K; Löning T; Bamberger AM
Virchows Arch; 2008 Jul; 453(1):89-96. PubMed ID: 18415123
[TBL] [Abstract][Full Text] [Related]
2. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
3. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
4. Significantly decreased P27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression).
Ozkara SK; Corakci A
Pathol Oncol Res; 2004; 10(2):89-97. PubMed ID: 15188025
[TBL] [Abstract][Full Text] [Related]
5. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis.
Sherman ME; Bur ME; Kurman RJ
Hum Pathol; 1995 Nov; 26(11):1268-74. PubMed ID: 7590703
[TBL] [Abstract][Full Text] [Related]
6. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
[TBL] [Abstract][Full Text] [Related]
7. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
[TBL] [Abstract][Full Text] [Related]
8. MSX1-A Potential Marker for Uterus-Preserving Therapy of Endometrial Carcinomas.
Eppich S; Kuhn C; Schmoeckel E; Mayr D; Mahner S; Jeschke U; Gallwas J; Heidegger HH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630554
[TBL] [Abstract][Full Text] [Related]
9. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
Li C; Zota V; Woda BA; Rock KL; Fraire AE; Jiang Z; Lu D; Xu B; Dresser K; Lutman CV; Fischer AH
Mod Pathol; 2007 Dec; 20(12):1263-8. PubMed ID: 17885673
[TBL] [Abstract][Full Text] [Related]
10. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
11. Uterine sarcomas: a review.
D'Angelo E; Prat J
Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
[TBL] [Abstract][Full Text] [Related]
12. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
13. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis.
Reid-Nicholson M; Iyengar P; Hummer AJ; Linkov I; Asher M; Soslow RA
Mod Pathol; 2006 Aug; 19(8):1091-100. PubMed ID: 16648864
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in uterine sarcoma.
Gadducci A
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):783-95. PubMed ID: 21764643
[TBL] [Abstract][Full Text] [Related]
16. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53.
Ambros RA; Vigna PA; Figge J; Kallakury BV; Mastrangelo A; Eastman AY; Malfetano J; Figge HL; Ross JS
Cancer; 1994 Mar; 73(6):1686-92. PubMed ID: 8156496
[TBL] [Abstract][Full Text] [Related]
17. Hysteroscopic and immunohistochemical findings in type I and type II endometrial carcinomas.
Maia H; Maltez A; Fahel P; Coutinho E
J Am Assoc Gynecol Laparosc; 2001 May; 8(2):222-30. PubMed ID: 11342729
[TBL] [Abstract][Full Text] [Related]
18. Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications.
Orlandi A; Ferlosio A; Ciucci A; Francesconi A; Lifschitz-Mercer B; Gabbiani G; Spagnoli LG; Czernobilsky B
Mod Pathol; 2006 Jun; 19(6):797-803. PubMed ID: 16575402
[TBL] [Abstract][Full Text] [Related]
19. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
20. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.
Singh M; Spoelstra NS; Jean A; Howe E; Torkko KC; Clark HR; Darling DS; Shroyer KR; Horwitz KB; Broaddus RR; Richer JK
Mod Pathol; 2008 Jul; 21(7):912-23. PubMed ID: 18487993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
